GlassScriptPhysician profile
Allison F Singer
NPI 1720086846
$15,722.20
in general payments reported to CMS, 2019-2025
41 companies · $3,425 in 2025
The $3,425 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $914 · 2021: $1,076 · 2022: $2,027 · 2023: $2,973 · 2024: $3,822 · 2025: $3,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,039.93 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,239.51 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,342.04 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $1,266.23 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Janssen Biotech, INC. | $1,249.23 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,125.87 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $886.17 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $709.55 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $673.88 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $557.59 | 2021-2025 | |
| Genzyme Corporation | $530.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $516.58 | 2019-2025 | |
| Dermavant Sciences, INC. | $497.67 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $494.33 | 2020-2021 | |
| Amgen INC. | $473.64 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $456.00 | 2021-2025 | Adbry, Anzupgo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $415.87 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $332.89 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Revance Therapeutics, INC. | $255.66 | 2024 | Daxi, Daxxify |
| Ucb, INC. | $231.89 | 2019-2025 | Bimzelx |
| Almirall LLC | $206.49 | 2019-2025 | Seysara, Klisyri |
| Prugen, INC. Pharmaceuticals | $125.00 | 2019-2020 | |
| Epi Health, LLC | $124.27 | 2019-2022 | |
| Encore Dermatology INC. | $121.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.70 | 2023-2025 | Spevigo, Cyltezo |
| Mayne Pharma Commercial LLC | $94.75 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.90 | 2022-2024 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $88.54 | 2019-2023 | |
| Organon LLC | $73.71 | 2025 | Vtama |
| Nabriva Therapeutics, Plc | $69.51 | 2021-2022 | |
| Dermira, INC. | $65.89 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $51.91 | 2023-2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $41.63 | 2019 | |
| Journey Medical Corporation | $34.52 | 2022 | |
| Sandoz INC. | $24.93 | 2019 | |
| Botanix Sb INC | $24.53 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $22.68 | 2019 | |
| Glaxosmithkline, LLC. | $21.44 | 2020 | |
| Biofrontera INC. | $19.12 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $18.93 | 2019 | |
| Genentech USA, INC. | $13.61 | 2020 | |
| Promius Pharma LLC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.